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c TÜBİTAK
⃝
doi:10.3906/kim-1701-41

Research Article

Impurity profiling of morphine by liquid chromatography-heated electrospray
ionization mass spectrometry (LC-HESI-MS)
Ana PETKOVSKA1,∗, Jelena ACEVSKA2 , Marina CHACHOROVSKA1 ,
Gjorgji PETRUSEVSKI1 , Gjoshe STEFKOV3 , Rumenka PETKOVSKA2 ,
Aneta DIMITROVSKA2 , Sonja UGARKOVIC1
1
Research & Development, Alkaloid AD, Skopje, Republic of Macedonia
2
Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, ‘Ss. Cyril and Methodius”
University, Skopje, Republic of Macedonia
3
Institute of Pharmacognosy, Faculty of Pharmacy, “Ss. Cyril and Methodius” University, Skopje,
Republic of Macedonia
Received: 18.01.2017

•

Accepted/Published Online: 06.06.2017

•

Final Version: 20.12.2017

Abstract: Separation of morphine and its impurities (related substances specified in relevant European Pharmacopoeia
monographs, as well as the other naturally occurring coextracted alkaloids) was obtained within a close retention
window on a reverse phase HPLC column, eluted with optimized gradient, consisting of methanol and 5 mM ammonium
formate, adjusted to pH 10.2. Systematic optimization of the chromatographic conditions was carried out using design of
experiments. According to their mass spectra, known and specified impurities were identified and tentative structures for
unknown impurities were proposed. MS analyses were performed in positive ionization mode using heated electrospray
ionization. Fragmentation patterns of the eluted compounds under optimized mass spectrometry conditions indicated
that all detected impurities are structurally related to morphine.
Key words: Impurity profiling, LC-DAD-HESI-MS n , morphine, design of experiments

1. Introduction
Impurity profiling is strongly related to detecting, understanding the mechanism of action, and preventing side
eﬀects of medicines; therefore, analytical monitoring of impurities in active pharmaceutical ingredients (APIs)
is a key component of drug development. 1,2 This indicates that the quality control of APIs should always be
supported by additional purity profiling, based on the information obtained from the manufacturing process. 3
Furthermore, the impurity profiling represents part of an analytical strategy used for combating falsification of
medicines. 4−6 Our previous work demonstrated that profound understanding of impurity profile is the key to a
better understanding of the origin and diﬀerentiation of API samples. 7−9
Considering the fact that morphine is isolated from a natural product, the profile of impurities largely
encompasses organic compounds with similar structures. It is very likely that the most abundant poppy alkaloids
would be coextracted under extraction conditions of morphine. Organic impurities with similar structure to
morphine can be characterized using HPLC, as suggested in the European Pharmacopoeia (Ph.Eur). 10 However,
the list of specified impurities does not indicate other alkaloids (e.g., thebaine, noscapine, papaverine), their
biosynthetic intermediates, degradation products, and other classes of alkaloids. Since HPLC retention times
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may vary, uncertainty can arise as to whether a peak in a new retention time means a new impurity. Therefore,
when impurity standards are not available, the method should provide online characterization, such as mass
spectrometry (MS), as a detection tool in further determination of the unknown and unspecified impurities.
This work attempts to assess the ability of LC-MS n to generate characteristic impurity fragmentation
pathways, composed of a molecular ion mass, plus at least three fragmentation steps. 11,12 Our previous research
on API authentication and prevention of falsification, based on the impurities detected in morphine samples 7
and assessment of the qualitative profile of alkaloids in poppy straw, 13−15 pointed out the necessity of online
characterization of the present analytes. Thus the aim of this part of the research was to advance LC method
identification performances of a suitable ‘MS friendly’ HPLC method for separation and identification of
morphine and its known and unknown related substances and possible degradation products, using a welldesigned strategy for optimization and robustness verification. 16−19
2. Results and discussion
2.1. Optimization of the chromatographic conditions
In order to optimize the chromatographic conditions, 2 3 central composite face centered design of experiments
(CCFC DoE) was employed, which involved a set of 11 planned experiments, and investigation of two experimental factors: buﬀer concentration (x1), in a range from 1 to 10 mM, and buﬀer pH value (x2), in a range from
9.0 to 10.2. The chromatographic response was assessed through the critical resolutions (between morphine and
impurity E and between morphine and impurity B) and the retention factor of impurity F. The results obtained
during the method optimization are summarized in Table 1. The eﬀects of the diﬀerent experimental conditions
on the defined chromatographic responses are shown through the normalized coeﬃcients of the CCFC design
(Figure 1). The alteration of the chromatographic responses over the defined area of the experimental factors
was assessed using response surface methodology (RSM) (Figure 2).
Table 1. Experimental data for assessment of the chromatographic response during the method optimization.

Experiment no.
N1
N2
N3
N4
N5
N6
N7
N8
N9
N10
N11

x1 (buﬀer conc., mM) x2 (buﬀer pH)
1
9
10
9
1
10.2
10
10.2
1
9.6
10
9.6
5.5
9
5.5
10.2
5.5
9.6
5.5
9.6
5.5
9.6

Rs1 (imp.E/MO)
1.35
1.81
4.56
5.93
2.05
3.46
2.01
5.81
3.26
3.26
3.22

Rs2 (MO/Imp.B)
0.0
5.0
0.0
9.4
0.0
5.3
4.0
10.7
6.1
6.1
6.1

k’ (imp.F)
1.2
1.2
0.6
0.7
0.9
1.1
0.9
0.7
1.1
1.1
1.1

The results of the chemometric experiments showed that all factors aﬀected the chromatographic parameters. Critical resolution between impurity E and morphine was perceived, and impurity F was eluted in
the column void time (1.4 min). By increasing the buﬀer concentration and the pH of the buﬀer, impurity
E/morphine resolution (Figure 2a) and impurity B/morphine resolution (Figure 2b) was enhanced. The retention factor (k ′ value) for the first eluted peak (impurity F) was increased (above 1, which was set as target
minimum value) by increasing the buﬀer concentration and decreasing the buﬀer pH value (Figure 2c). However,
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Figure 1. Normalized coeﬃcients of the 2 2 CCFC DoE showing the eﬀects of diﬀerent chromatographic conditions:
b1 (buﬀer concentration), b2 (buﬀer pH value) and their interactions (b11, b22, b12) on the chromatographic descriptors (resolution between critical pairs of analytes and retention factors of the first eluting peak) during the method
optimization by use of chemometrics.
(a)

(b)

(c)

Figure 2. Contour diagram presenting the eﬀect of the experimental factors; buﬀer concentration (x1) and buﬀer pH
value (x2) on the critical resolutions: a) impurity E/MO (y1), b) MO/impurity B (y2), and c) retention factor of impurity
F (y3).

the lowest possible buﬀer concentration is desirable for better sensitivity of the mass spectrometer. As for the
pH value, attention should be paid to the column stability. According to the RSM results shown in Figure 3,
the chromatographic conditions were optimized. Since the operational pH range of the column was to 11.5, the
906
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maximal value was chosen (10.2), considering also the buﬀer capacity. For the buﬀer concentration, a mid value
was chosen, since both critical resolutions were above the target value of 2.0 (Figures 3a and 3b). As for the
retention factor of impurity F, the content of organic solvent (MeOH) was decreased in order to keep the value
above 1.0 (Figure 3c).
(a)

(b)

(c)

Figure 3. Results obtained from testing the robustness of the methods (2 2 Full Factorial Quadratic Design of Experiment) - The eﬀects of changes in diﬀerent analytical conditions during the robustness testing of the method; x1 – buﬀer
concentration (4–6 mM) and x2 – buﬀer pH (10.0–10.4) on the chromatographic response: a) y2 – resolution between
impurity E/morphine, b) y3 – resolution between morphine/impurity B and c) y1 – retention factor (impurity F).

2.2. Method validation
Under the proposed chromatographic conditions all analytes were completely separated (Figure 4). Results
from method validation, in accordance with International Conference on Harmonization (ICH) guidelines Q2
R1 20 showed satisfactory specificity, linearity, sensitivity, precision, accuracy, and robustness. The number of
theoretical plates (N) for all analytes (N > 5000) indicates a good separation eﬃciency of the applied column.
Capacity factor values for all peaks were between 2 and 10. All peaks have good shape, with symmetry factor
(As) values between 0.8 and 1.2.
The linearity of the method was demonstrated for morphine reference solutions ranging from 1.275 to
11.475 µ g/mL (0.05%–0.45% of the morphine working concentration). The results obtained from the regression
analysis of the peak area (y) versus concentration (x) data indicated that the method was linear (y = 13.931x
– 3.8973, R 2 = 0.9999).
The limit of detection (LOD) and limit of quantification (LOQ) were determined from the residual
standard deviation of the regression line (σ) and the slope (S) in the concentration range from 1.275 to 11.475
µ g/mL (0.05%–0.45% of the morphine working concentration). The LOD for morphine (3.3 σ /S) is 0.15 µ g/mL
(0.006% of the morphine working concentration), which is within the acceptance criteria (LOD was ≤ 0.05%
907
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Figure 4. UV chromatogram of morphine and its known impurities.

of the morphine working concentration (Ph.Eur disregard limit (10)), i.e. ≤ 1.275 µ g/mL). The LOQ value
(10 σ /S) was 0.44 µ g/mL (0.017% of the morphine working concentration), which is much less than level of
specification (0.2% of the morphine working concentration).
The repeatability was performed by analyzing six replicate injections of an impurity standard solution
at 100% of the specified limit with respect to the working strength of API (0.2% of the morphine working
concentration for each impurity, except for impurity B: 0.4% of the morphine working concentration). The
percentage relative standard deviations of peak areas (n = 6) were less than 2.0% for each impurity, which
indicated acceptable repeatability of the method. Additionally, precision at LOQ was performed by analyzing
three replicate injections of a standard solution of morphine at LOQ level and the percentage relative standard
deviation was less than 5.0%.
The accuracy of the method was assessed by comparison of the results of the proposed analytical
procedure with those of a second well-characterized procedure, i.e. method for related substances described in
Ph.Eur monographs on morphine hydrochloride trihydrate (04/2008:0097) and morphine sulfate pentahydrate
(04/2008:1244), since the impurity and degradation product standards are unavailable. The bias for individual,
unknown impurities obtained by the two methods was not more than the acceptance criterion of ±0.03 and the
bias for total impurities was within the acceptance criterion of ± 0.10.
The amount of each impurity [% m/m] present in the test solution (morphine concentration about
2.5 mg/mL) was calculated using the peak due to morphine obtained with reference solution (diluted test
solution to about 0.005 mg/mL, i.e. 0.2% solution relative to test solution) as external reference. For the
purpose of the study (API fingerprinting) no peak was disregarded.
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2.3. Robustness validation
Within method validation, suitability of the chromatographic system was demonstrated using mixed standard
solution, containing related substances specified in the Ph.Eur monographs on morphine hydrochloride trihydrate (04/2008:0097) and morphine sulfate pentahydrate (04/2008:1244): 10 impurity A (codeine), impurity
B (2,2’-bimorphine), impurity C (oripavine), impurity D (10S-hydroxymorphine), impurity E (morphinone),
and impurity F (morphine N-oxide), as well as other naturally occurring coextracted (commercially available)
alkaloids: thebaine, noscapine, and papaverine.
Specificity was demonstrated by showing that the peaks were acceptably resolved, by performing peak
purity tests using diode array detector and mass spectrometry. Additionally, specificity was proved by comparing
the impurity profiles of API samples obtained with the pharmacopeial method for determination of related
substances of morphine, described in the relevant Ph.Eur monographs.
Since robustness testing of analytical methods 20 requires extensive experimental work (where intentional
changes in experimental conditions are made and studied), here an accurate and rational assessment of the
robustness of the method was done by use of chemometrics. Minor changes in experimental factors values were
made by performing a set of 12 experiments defined by the 2 2 full factorial quadratic design of experiments
(Table 2). The following method parameters were altered in order to test the robustness: buﬀer concentration
(x1 ), in a range ±1 mM from the proposed concentration of 5 mM (corresponding to maximum 20% variation of
the system suitability criteria 21,22 ) and buﬀer pH (x2 ) , in a range ± 0.2 pH value from the proposed pH = 10.2
(corresponding to recommended maximum variation of pH. 20 ) These method parameters were determined as
critical during method optimization by use of chemometrics. System suitability solutions were analyzed to assess
if these changes had a significant eﬀect on the defined method parameters. The chromatographic response was
assessed through the critical resolutions (between morphine and impurity E and morphine and impurity B) and
the retention factor of impurity F.
System suitability criteria for the method should be fulfilled, i.e. the critical resolutions between morphine
and impurity E and morphine and impurity B should be above 2.0 and the retention factor of impurity F should
be above 1.0. Table 2 and Figure 4 summarize the results of the robustness study. The small changes in buﬀer
concentration (± 1 mM) and pH of the mobile phase (± 0.2) did not change significantly the chromatographic
responses defined within the acceptance criteria (Figure 3). The critical resolutions between morphine and
impurity E and morphine and impurity B remained above 2.0 (Figures 3a and 3b) and the retention factor of
impurity F was around the defined value of 1.0 (Figure 3c). However, the retention factor of impurity F was
found to be aﬀected at low buﬀer concentration (4 mM) and high pH values (pH 10.4), especially when the
experimental factors were changed simultaneously. Therefore, it is recommended to maintain buﬀer pH at 10.2
± 0.05 and buﬀer concentration at 5 ± 0.5 mM.
2.4. Identification of morphine impurities using mass spectrometry
The starting material and known impurities under investigation are alkaloids containing basic nitrogen, which
makes them preordained for electrospray ionization in positive ionization mode. In order to test mass spectrometer selectivity, this method was optimized with analysis of mixed standard solution containing all pharmacopeia
impurities and related substances listed in Table 3: morphine N -oxide (impurity F), 10-S -hydoxymorphine
(impurity D), morphinone (impurity E), 2,2’ bimorphine (impurity B), oripavine (impurity C), codeine (impurity A), papaverine, phebaine, and noscapine. Figure 4 shows a UV chromatogram of all the impurities present
in mixed standard solution.
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Table 2. Summary of data for robustness study parameters altered to test method robustness, using the 2 2 full factorial
quadratic design of experiments.

Parameters of the method (factors)
Experiment
N1
N2
N3
N4
N5
N6
N7
N8
N9
N10
N11
N12

x1 (mM)

x2 (pH)

4
5
6
4
5
6
4
5
6
5
5
5

10.0
10.0
10.0
10.2
10.2
10.2
10.4
10.4
10.4
10.2
10.2
10.2

Chromatographic descriptors (responses)
Rs1(Imp.E/ Rs2(morphine/
k’(imp.F)
morphine)
Imp.B)
1.09
2.09
2.32
1.03
2.15
5.57
0.97
2.44
4.96
0.97
2.69
3.28
1.03
2.21
3.74
0.95
2.46
5.30
0.79
2.68
4.16
0.88
7.73
4.83
0.91
2.40
6.11
1.03
2.18
3.74
1.03
2.19
3.72
1.03
2.13
3.71

Table 3. Fragments, retention times, and relative retention times of known impurities, analyzed with the LC-MS
method.

MS3
174; 201; 211;
2.8 0.31 202; 212; 292
302
284; 267
215; 229; 268
162; 201; 211;
5.5 0.60 224; 260
302
201; 227; 284
215; 229; 268
8.3 0.90 236; 272; 348; 372 284
227; 284
209
201; 211; 215; 173; 155; 165;
9.2 1.00 218; 236; 286
286
229; 268
237;193; 185
10.5 1.14 242; 314; 370
569, 286 551
437
10.9 1.19 228; 286; 352
298
267
249
12.3 1.34 222; 284
300
215; 243, 282 182
14.1 1.53 238; 278; 341
340
202;
170
15.3 1.66 232; 284
312
281; 249
249; 266
17.9 1.95 220; 292; 312
414
220
204

Peak name
Morphine N -oxide
(Imp F)
10-S-hydoxymorphine
(Imp D)
Morphinone (imp E)

MW rt

Morphine

285

301
301
283

2,2’ Bimorphine (imp B) 568
Oripavine (imp C)
297
Codeine (imp A)
299
Papaverine
339
Thebaine
311
Noscapine
413

RRt λmax

MH+

MS2

MW– molecular weight; rt – retention time; RRt – relative retention time; MH + – parent ion m/z; MS 2 , MS 3 –
fragments, most abundant ions are marked in bold

The first challenge for this mass spectrometry method was to distinguish morphine N -oxide (impurity F)
from 10-S -hydoxymorphine (impurity D), which are structural isomers with molar mass 301. Namely, impurity
D diﬀers from morphine by one hydroxyl group attached to position C-10 on morphine B ring opposite from
impurity F, which includes one oxygen atom attached to nitrogen (position 17) and forms morphine N-oxide.
According to the obtained mass spectra from experimental data, impurity F (molecular weight 301,
[M + H] + = 302), as unstable morphine N-oxide radical, immediately transforms to m/z 285 (most abundant
peak in MS 2 ), followed by loss of 16 amu, which implies loss of oxygen. The presence of m/z 268 in impurity
F’s MS 2 spectra indicates loss of 35 amu due to morphine ring E opening and detaching of the CH 3 NCH 2 group.
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Mass spectra obtained for impurity D (molecular weigh 301, [M + H] + = 302) show the most abundant
mass spectra m/z 227 due to loss of 75 amu (loss of CH 3 and morphine ring D). Unlike impurity F, ion m/z
284 is present here, which indicates loss of 18 amu (H 2 O) from the parent compound. Both impurities in their
MS 3 spectra show fragments 162 and 201, as part of morphine fragmentation. This indicates that although
impurities F and D are structural isomers they can be distinguished by their fragmentation pathways. In the
absence of specific standards for these impurities, for the MS part of this method information from mass spectra
was used as a verification tool and it was defined that impurity F occurs at a retention time of about 2.83 and
impurity D occurs at a retention time of about 5.4 min.
Additionally, morphine base (MoB), morphine sulfate (MoS), and morphine hydrochloride (MoH) samples
were analyzed and eﬀort was made to identify the following unknown impurities/morphine related products and
keeping in mind the mass spectrometry results, the most probable structures of these impurities were suggested.
All discussed fragments of unknown impurities are summarized in Table 4.
Table 4. Fragments, retention times, and relative retention times of unknown impurities found with LC-MS method in
14 diﬀerent morphine samples. 7

Peak name

rt

RRt

λmax

MH+

MS2

Impurity X1

6.2

0.68

220; 232; 280

344

328

Impurity X2

6.9

0.75

220; 232; 278

388

372; 344

Impurity
Impurity
Impurity
Impurity
Impurity
Impurity
Impurity
Impurity
Impurity
Impurity
Impurity

7.1
7.8
10.8
11.4
11.6
11.7
10.4
13.6
14.0
14.4
7.5

0.78
0.85
1.18
1.24
1.27
1.28
1.14
1.48
1.53
1.57
0.82

235;
235;
235;
218;
218;
218;
218;
242;
242;
242;
220;

286, 476
520; 286
569, 286
284
284
284
358
572
572
572
327

459; 415
503; 269;
551
227; 284
227; 284
227; 284
201; 286;
201; 286;
201; 286;
201; 286;
284; 133

X3
X4
X5
X6
X7
X8
X9
X10
X11
X12
X13

268
268
268
236;
236;
236;
236;
314;
314;
314;
232;

286
286
286
286
370
370
370
280

520

229;
229;
229;
229;

268
268
268
268

MS3
211; 225; 237;
250; 268; 286;
211; 225; 237;
250; 268; 286;
176; 371
176; 162
437
209
209
209
174; 162
174; 162
174; 162
174; 162
133

MW– molecular weight; rt – retention time; RRt – relative retention time; MH + – parent ion m /z; MS 2 , MS 3 –
fragments, most abundant ions are marked in bold

Unknown impurity X1 with RRt = 0.68 shows a molecular ion peak with m/z 344, which in the second
step of fragmentation indicates clear MS 2 spectra where the only present peak is m/z 328 (loss of 17 amu,
which indicates on hydroxyl group). This peak m/z 328 indicates a well-known morphine-related compound
monoacetylmorphine that gives rise to product ions similar to those of protonated morphine. The ion at m/z
286 is formed by deacetylation (loss of ketene) from m/z 328. The base peak at m/z 268 can be produced either
by direct loss of acetic acid from m/z 328 or by loss of H 2 O from m/z 286. The MS 3 spectrum of m/z 268
results in product ions at m/z 250 (268- H 2 O), 237, 225, and 211 formed by partial cleavage of the piperidine
ring, as described by Zhang et al. 23
As additional confirmation of the X1 structure, unknown impurity X2 structure was suggested. This
impurity at RRt = 0.75 has a molecular ion peak m/z 388, which points to the morphine-related structure
diacethyloxymorphine. Furthermore, this structure shows fragments m/z 344, which indicates the monoacethyl911
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morphie structure and m/z 372 as the most abundant peak in the second step of fragmentation, explained as
a result of loss of 17 amu (hydroxyl group). MS 3 spectra from the parent compound m/z 388 present three
interesting peaks, such as m/z 328, previously explained as product of 344; m/z 250, 237, 225, and 211, which
points to a morphine nucleus as in structure X1.
Impurity marked with X3 at RRt = 0.78 points to morphine due to the presence of ion m/z 286 and
ion m/z 476 in the full mass spectra. Most probably m/z 476 (diﬀerence from bimorphine 93 amu) is a
bimorphine-like structure, consisting of one morphine core attached to A, B, and D morphine rings, as residuals
from the second morphine. The second step of fragmentation points to a loss of hydroxyl group to form ion
m/z 459, which in the third step of fragmentation undergoes cleavage of one CH 3 CH 2 NH- group from one
morphine E ring (loss of 44 amu) to form m/z 415 and also cleavage of two CH 3 CH 2 NH- groups (loss of 88
amu) to form m/z 371. The most abundant peak in the MS 3 spectra is ion m/z 176, which indicates loss of
286 amu and confirms the suggested structure.
At RRt = 0.85 unknown impurity X4 with m/z 520 was investigated. The obtained MS 3 spectra of
this impurity confirms m/z 176 ion (loss of morphine structure 286 amu) as well as all ions discussed in the
MS 3 spectra of impurity X3. The first step of fragmentation of X4 also indicates a bimorphine-like structure,
whose most abundant ions are m/z 520 and m/z 286, followed by loss of 17 amu (hydroxyl group) in MS 2 ,
confirmed by peaks m/z 503 and m/z 269, respectively. The suggested structure of this impurity diﬀers from
a bimorphine structure by 48 amu. These observations lead to the conclusion that this impurity with m/z 520
most probably consists of two morphine structures, one with detached CH 3 CH 2 NH- group and saturated C-C
bonds on both morphine B rings.
Impurity X5 at RRt = 1.18 (which is very close retention time to the main compound, morphine) shows
the same full mass spectra and fragments as morphine. The fragmentation of morphine and most abundant
ions are explained above and confirmed by the literature. 24−30 Diﬀerence in retention time of morphine and
unknown impurity X5 (higher retention) indicates that the unknown compound is less polar than morphine,
which most probably originates from diﬀerent arrangement of hydroxyl groups or substitution of less polar
groups with the same mass as OH groups on morphine rings B and A. All of the above-mentioned information
suggests that morphine and impurity X5 are structural isomers with the same molar mass; the same fragments
but diﬀerent polarity equals diﬀerent retention time.
A group of impurities at RRt 1.24 (X6), 1.27 (X7), and 1.28 (X8) points to dihydromorphone-like
structures or, in other words, dihydromorphone structural isomers, with the same m/z 284 (dihydromorphone
molecular mass is 283) and the same fragmentation until MS 3 but diﬀerent polarity due to diﬀerent arrangement
of the same substituent, which in this case can only be diﬀerent substitution of the –OH group on the
dihydomorphone structure.
Unknown impurity X9 at RRt 1.14, present only in one MoB sample, 7 shows mass spectra with m/z
358. In MS 2 this impurity is followed by loss of 72 amu to form only one most abundant peak ion m/z
286 (morphine), which is followed by fragmentation, the same as morphine fragmentation in MS 3 . The most
probable structure of this impurity is morphine with substituent of 72 amu (CH3-CH-CH 2 CH 2 OH) on position
2 on morphine A ring.
Peaks at RRt 1.48, 1.53, and 1.57 (X10, X11, and X12) are probably bimorphine-like structures with
saturated double bonds on morphine rings A or C. These three impurities in the full mass spectra range show
m/z 572, which is a diﬀerence of only one saturated double bond from the bimorphine original structure. It is
912
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assumed that this saturation influences the retention time (diﬀerent from all other bimorphine-like structures
discussed above). As all previously discussed bimorphines, in the first fragmentation step all of the three
compounds lose 17 amu, followed by loss of 286 to form m/z 176. Unknown structures X10-12 diﬀer in
intensity abundance of ion peaks in MS 2 and therefore it can be concluded that they are structural isomers.
Unknown impurity X13 with RRt = 0.82 shows a molecular ion peak with m/z 327, which in MS 2 shows
fragments, such as m/z 133, which is probably the most stable metoxybenzyl radical (formed with loss of 194
amu) and peaks with m/z 284 as a result of a loss of 43 amu in the form of a CH 3 C= O group. The presence
of metoxybenyl radical (note that monoacetyl group is attached on the morphine ring C) plays a crucial role in
morphine structure fragmentation 21,22,30 and the mass spectra of this impurity indicate that this impurity is a
monoacetylmorphine derivate.
In this work, a suitable “MS friendly” HPLC method for separation and identification of morphine and
its known and unknown related substances and possible degradation products was developed and successfully
employed for origin determination of morphine samples using pattern recognition techniques. 7 That part of the
research proved the applicability of the method and highlighted its advantages over the existing pharmacopoeial
HPLC method for determination of related substances of morphine, 10 regarding authentication and prevention
of falsification.
The method for separation of morphine-related compounds proposed by Ph. Eur, using anionic ionpairing agents at acidic pH to avoid peak tailing, is not convenient for coupling with mass spectrometer due
to the nonvolatility of the ion-pair reagents. In order to avoid use of ion-pairing agents, we searched for an
alternative mobile phase. Due to the basic nature of morphine impurities (morphinane core), good separation
was obtained at alkaline pH, where the amine group would not be ionized. This is generally not possible
with bonded silica-based columns because of the instability of the silica matrix at alkaline pH. 20−22 A reversedphase columns with bidentate C18-C18 bonding technology that prevents interactions between noncharged basic
compounds with the underlying silica at high pH was chosen as a stationary phase. 31 Some of the mobile phase
buﬀer options for high pH included trifluoroacetic acid (TFA), trichloroacetic acid (TCA), ammonium acetate
(AmAc), and ammonium formate (AmF) in combination with ammonia. TCA and AmAc did not provide a
satisfactory solution, unlike TFA, but in this case the large ion reduced the sensitivity of the mass spectrometer.
The optimal chromatographic and mass spectrometry conditions were obtained using AmF in combination with
ammonia for pH adjustment. As for the choice of a UV wavelength, although morphine-related compounds
have absorption maxima around 283 nm, 230 nm was used for detection in order to expose morphine N-oxides.
An additional step of heating the mobile phase and sample mixture prior to ionization (heated electrospray
ionization (HESI)) was used to maintain a high flow rate of the mobile phase of 1 mL/min in order to achieve
faster analysis time and at the same time accomplish vaporization of the mobile phase before ionization. During
method optimization, both ESI and HESI modes were tested and it was concluded that the additional heating
of the probe does not induce additional degradation of morphine.
Using DoE results, the separation of all the impurities was obtained with an optimized gradient elution
with methanol and 5 mM ammonium formate, pH adjusted to 10.2. All compounds were fully resolved and
eluted within 20 min and satisfactory ionization and mass spectrometer sensitivity were achieved. After method
validation, closer examination of the results obtained from mixed standard solutions presented in Table 3
suggests that all morphine-related compounds undergo similar fragmentation patterns as morphine, after their
side chains or function groups detach. In previous years, soft ionization methods were intensively used for
investigation of morphine and its metabolites, 24−34 versus the electron impact (EI) mass spectra of morphine
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and morphine-related compounds, which were elaborated at the end of the last century. 24−27 The results
obtained from comparative study of an ion trap mass spectrometer and a triple quadrupole system revealed
that the MS 2 spectrum of morphine (m/z 286) contains major product ions at m/z 268, 229, 211, and 201,
and minor ions at m/z 237, 193, 185, 173, 165, and 155. The base peak at m/z 201 is derived from m/z 286 by
partial cleavage of the piperidine ring and consecutive losses of an amine (CH 2 CHNHCH 3 ) and CO. 27,28 Since
a detailed explanation of the fragmentation of morphine, codeine, thebaine, and oripavine has been presented
previously, 23 only the unspecified impurities are discussed in the section results.
3. Experimental
3.1. Chemicals and reagents
Morphine for system suitability CRS, containing Ph.Eur specified impurities B (2,2’-bimorphine), C (oripavine),
E (morphinone), and F (morphine N-oxide), was purchased from EDQM. Working standards for Ph.Eur impurity
A (codeine) and the naturally occurring alkaloids, thebaine, papaverine, and noscapine, as well as the samples,
morphine hydrochloride trihydrate (MoH), morphine sulfate pentahydrate (MoS), and morphine base (MoB),
were obtained from Alkaloid A.D. Skopje (Skopje, R. Macedonia).
Methanol (MeOH, HPLC grade), sodium heptanesulfonate (pa), and phosphoric acid (pa) were purchased
from Merck, Darmstadt, Germany. Acetic acid (pa), ammonium formate (pro analysis), and formic acid (pa)
were purchased from Sigma-Aldrich (Steinheim, Germany). Water (highly purified) was obtained with a TKALAB Reinstwasser system (Niederelbert, Germany).
3.2. Sample preparation
Mixed standard solution was prepared by dissolving 5 mg of morphine for system suitability CRS in MeOH,
adding 100 µ L of the corresponding methanol stock solution (concentration of 1 mg/mL) of codeine (Ph.Eur
impurity A), thebaine, papaverine, and noscapine, and diluted to 2 mL with MeOH. Sample solution was
prepared by dissolving about 0.125 g of the substance to be examined in MeOH and diluted to 50 mL with
the same solution. Reference solution, used for the calculation of each impurity’s content, 7 was prepared by
dilution of 1.0 mL of the test solution to 100.0 mL with MeOH and further dilution of 2.0 mL of this solution
to 10.0 mL with MeOH. All samples and standards were prepared in duplicate. Each sample preparation was
injected twice in the HPLC system. Six replications of each quantification standard were injected on a daily
basis to confirm repeatability of the HPLC system. In order to check the performance of the HPLC system, prior
to every analysis system suitability solution containing all known impurities was analyzed. Standards, samples,
and system suitability solutions used for method validation were prepared and injected as recommended by ICH
guidelines Q2 R1. 20
3.3. Instrumentation and LC-MS conditions
The analysis was performed on a Thermo Scientific Dionex Ultimate 3000 UHPLC-UV-DAD system consisting
of a Thermo Scientific Dionex Ultimate 3000 pump, Thermo Scientific Dionex Ultimate 3000 injector, Thermo
Scientific Dionex Ultimate 3000 Column Thermostat Compartment, and Thermo Scientific Dionex Ultimate
3000 diode array detector associated with a Thermo Scientific LTQ XL linear ion trap mass spectrometer
equipped with a HESI probe and controlled by Chromeleon 5.0 and Xcalibur 2.0 software. The separation
of the detected impurities was achieved on a Zorbax Extend C18 column (Agilent Technologies), 250 mm ×
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4.6 mm i.d., and 5 µm particle size. Elution was performed at flow rate of 1.0 mL/min, using mobile phase
consisting of MeOH and ammonium formate buﬀer (5 mM; pH 10.2 adjusted using 25% ammonia solution)
with the following gradient: 0–1 min 15% MeOH; 1–5 min from 15% to 50% MeOH; 5–15 min from 50% to
75% MeOH; 15–20 min 75% MeOH; 20–25 min from 75% to 15% MeOH; 25–35 min 15% MeOH. The injection
volume was 10 µ L, the column temperature was maintained at 35 ◦ C, and detection was carried out at 230
nm.
The ESI probe needle temperature was 350 ◦ C, and the ion transfer tube was 325 ◦ C under sheath gas
(nitrogen) at 50 psi and auxiliary gas helium at 10 psi. Mass spectra were recorded in the range of 50–800
m/z, with maximum accumulation time of 500 ms. The collision-induced fragmentation was performed in an
ion trap using helium as collision gas at 3.5 eV. The specified impurities were confirmed by retention times and
UV spectra and all detected impurities (specified and unknown) were identified using their mass spectra and
fragmentation patterns.
3.4. Chemometrics
MODDE 10.1 software for DoE and optimization (Umetrics, Umea, Sweden) was used for optimization of
the experimental factors through an appropriate factorial design. The designed experiments were conducted
on a mixed standard solution. DoE was used to assess the influence of the ionic strength and the pH of the
mobile phase buﬀer on chromatographic responses (2 2 CCC DoE) and for the robustness testing during method
validation (2 3 CCC DoE).
4. Conclusion
The discussed results obtained in this study demonstrate that the proposed LC-DAD-HESI-MS method used
for impurity profiling of MoB, MoH, and MoS API samples represents a useful tool for online characterization
of known and unknown morphine-related impurities and degradation products. This LC-MS n method has
the ability to generate characteristic impurity fragmentation patterns, which consequently can be used as an
advanced tool for achieving improved identification performances. According to MS spectra, tentative structures
for detected unknown impurities were proposed, confirming that all detected impurities are structurally related
to morphine. Therefore, the suggested LC-MS method provides a broad ’analytical window’ in relation to the
identified impurities, which allows authenticity verification of APIs from various manufacturers.
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